-
GALT Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Galectin Therapeutics (GALT)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 27.06 mm | 27.06 mm | 27.06 mm | 27.06 mm | 27.06 mm | 27.06 mm |
Cash burn (monthly) | (no burn) | (no burn) | 3.02 mm | 3.30 mm | 2.85 mm | 2.81 mm |
Cash used (since last report) | n/a | n/a | 12.44 mm | 13.58 mm | 11.72 mm | 11.56 mm |
Cash remaining | n/a | n/a | 14.62 mm | 13.48 mm | 15.34 mm | 15.50 mm |
Runway (months of cash) | n/a | n/a | 4.8 | 4.1 | 5.4 | 5.5 |
13F holders | Current |
---|---|
Total holders | 85 |
Opened positions | 19 |
Closed positions | 7 |
Increased positions | 20 |
Reduced positions | 18 |
13F shares | Current |
---|---|
Total value | 24.94 bn |
Total shares | 9.75 mm |
Total puts | 1.98 mm |
Total calls | 1.16 mm |
Total put/call ratio | 1.7 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 2.13 mm | $5.87 bn |
BlackRock | 1.61 mm | $4.42 bn |
Advisor | 1.18 mm | $3.25 bn |
Geode Capital Management | 862.54 k | $2.37 bn |
Commonwealth Equity Services | 483.26 k | $1.33 mm |
Sontag Advisory | 398.37 k | $1.10 bn |
Geneos Wealth Management | 352.94 k | $970.57 mm |
STT State Street | 251.01 k | $690.29 mm |
MS Morgan Stanley | 246.08 k | $676.72 mm |
NTRS Northern Trust | 234.28 k | $644.27 mm |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Jan 25 | Gilbert S Omenn | Stock Option Common Stock | Grant | Acquire A | No | No | 1.23 | 60,000 | 73.80 k | 60,000 |
23 Jan 25 | Benjamin Carson SR | Stock Option Common Stock | Grant | Acquire A | No | No | 1.23 | 60,000 | 73.80 k | 60,000 |
23 Jan 25 | Jack W Callicutt | RSU Common Stock | Grant | Acquire A | No | No | 0 | 60,000 | 0.00 | 60,000 |
23 Jan 25 | Jack W Callicutt | Stock Option Common Stock | Grant | Acquire A | No | No | 1.23 | 65,000 | 79.95 k | 65,000 |
23 Jan 25 | Kary Eldred | Stock Option Common Stock | Grant | Acquire A | No | No | 1.23 | 60,000 | 73.80 k | 60,000 |
23 Jan 25 | Khurram Jamil | RSU Common Stock | Grant | Acquire A | No | No | 0 | 60,000 | 0.00 | 60,000 |
23 Jan 25 | Khurram Jamil | Stock Option Common Stock | Grant | Acquire A | No | No | 1.23 | 65,000 | 79.95 k | 65,000 |